Compounds for use as therapeutic agents affecting P53 expression and/or activity

US10538485B2 · kind B2 · utility

Assignees

• ABIVAX · FR
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
• INSTITUT CURIE · FR
• Universite De Montpellier · FR

Inventors

• Didier Scherrer · Castelnau-le-Lez, FR
• Jamal Tazi · Clapiers, FR
• Romain Najman · L'Haÿ-les-Roses, FR
• Florence Mahuteau · Le Puy-en-Velay, FR
• Pierre Roux · Argenteuil, FR

Key dates

• Filing date: Dec 13, 2017
• Grant date: Jan 21, 2020
• Expiry date: Dec 13, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a —NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C1-C4)alkyl group, a CONHR6 group, a —CONR7R8 group, a —SO2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a —(CH2)nNR7R8 group or a hydroxy(C1-C4)alkyl group; R6 represents a hydrogen atom, a —(CHR9)m(CH2)nNR7R8 group or a (C1-C6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the disclosure.